COX-2 inhibitors also synergized with chemotherapeutics and PD-1 blocking antibodies to resensitize resistant lung cancer cells, decrease metastasis, and eliminate immune evasion [19–22]. The gene discussed is PTGS2; the disease is lung carcinoma.